✅ Clarivate Hiring Associate STEM Content Analyst – Pharma Chem (0–2 Yrs, Chennai)
📍 Location: Chennai, India (Hybrid)
🎓 Eligibility: B.Pharm, M.Pharm, M.Sc (Chemistry)
🧪 Experience: 0 – 2 Years
💰 Salary: ₹3.8 – ₹6 LPA
📝 Job Type: Full-Time | Pharma Chem | Content Analyst Role
🔎 Verified: ✅ Verified Job via Medical Jobs India – hitechplus.in
🧬 About Clarivate
Clarivate is a global information services and analytics company that supports innovators worldwide. Through products like Derwent Innovation, Clarivate delivers trusted content in pharma, IP, research, and analytics to global institutions.
📄 Job Role: Associate STEM Content Analyst – Pharma Chemistry
This role involves indexing and coding chemical compounds found in patents for the Derwent Innovation database. You'll collaborate with global content teams and enhance your expertise in IP, chemistry, and analytics tools.
🧑💼 Key Responsibilities
- Code and index chemical compounds in pharma patents using Derwent conventions
- Analyze IUPAC names, reactions, and drug applications in global patent documents
- Use tools like Marvin JS, ISIS Draw to interpret molecular structures
- Work with content teams in India and UK to deliver quality chemical data
✅ Eligibility & Skills
- B.Pharm / M.Pharm / M.Sc (Chemistry)
- 0–2 years of pharma/chemical content analysis experience
- Strong analytical and documentation skills
- Knowledge of IUPAC nomenclature, Markush structures, and drug mechanisms
- Tools: Marvin Sketch, ISIS Draw, Outlook, MS Word, Excel
🌍 Nice-to-Have Skills
- Foreign language basics: German/French/Spanish (for patent translation)
- Experience in patent indexing, IP analytics, or content editing
🎁 Why Join Clarivate?
- 🧠 Global exposure in pharma-IP intersection
- 💼 Work on leading patent and chemical content platforms
- 📚 Upskill in data interpretation, scientific analysis, and indexing tools
- 🕒 Hybrid role with a 9 AM – 6 PM IST schedule
👇 Application Link Will Appear in 15 Seconds 👇
🟢 Verified Job via Medical Jobs India – hitechplus.in
.jpg)
.jpg)
0 Comments